1. Home
  2. LYRA vs SPHL Comparison

LYRA vs SPHL Comparison

Compare LYRA & SPHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LYRA
  • SPHL
  • Stock Information
  • Founded
  • LYRA 2005
  • SPHL 2002
  • Country
  • LYRA United States
  • SPHL Singapore
  • Employees
  • LYRA N/A
  • SPHL N/A
  • Industry
  • LYRA Medical/Dental Instruments
  • SPHL Homebuilding
  • Sector
  • LYRA Health Care
  • SPHL Consumer Discretionary
  • Exchange
  • LYRA Nasdaq
  • SPHL Nasdaq
  • Market Cap
  • LYRA 5.8M
  • SPHL 6.1M
  • IPO Year
  • LYRA 2020
  • SPHL 2024
  • Fundamental
  • Price
  • LYRA $24.28
  • SPHL $0.51
  • Analyst Decision
  • LYRA Buy
  • SPHL
  • Analyst Count
  • LYRA 2
  • SPHL 0
  • Target Price
  • LYRA $100.00
  • SPHL N/A
  • AVG Volume (30 Days)
  • LYRA 1.9M
  • SPHL 134.2K
  • Earning Date
  • LYRA 05-06-2025
  • SPHL 02-21-2025
  • Dividend Yield
  • LYRA N/A
  • SPHL N/A
  • EPS Growth
  • LYRA N/A
  • SPHL N/A
  • EPS
  • LYRA N/A
  • SPHL N/A
  • Revenue
  • LYRA $1,185,000.00
  • SPHL $6,456,601.00
  • Revenue This Year
  • LYRA N/A
  • SPHL N/A
  • Revenue Next Year
  • LYRA $1,286.17
  • SPHL N/A
  • P/E Ratio
  • LYRA N/A
  • SPHL N/A
  • Revenue Growth
  • LYRA N/A
  • SPHL N/A
  • 52 Week Low
  • LYRA $3.81
  • SPHL $0.35
  • 52 Week High
  • LYRA $37.50
  • SPHL $7.80
  • Technical
  • Relative Strength Index (RSI)
  • LYRA 76.38
  • SPHL N/A
  • Support Level
  • LYRA $22.22
  • SPHL N/A
  • Resistance Level
  • LYRA $27.42
  • SPHL N/A
  • Average True Range (ATR)
  • LYRA 4.12
  • SPHL 0.00
  • MACD
  • LYRA 2.36
  • SPHL 0.00
  • Stochastic Oscillator
  • LYRA 60.76
  • SPHL 0.00

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

About SPHL Springview Holdings Ltd Class A Ordinary Shares

Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.

Share on Social Networks: